Pancreatic Cancer Research

ResearcherHiroshima UniversityActive in the last 2 years

Takeshi Sudo

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5019321525. Sources: OpenAlex.

Their work

Papers
23 (first author 5, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
77
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: none · 2020: none · 2021: 1 paper · 2022: 3 papers · 2023: 2 papers · 2024: 4 papers · 2025: 2 papers · 2026: 5 papers

Papers 23

  1. Minichromosome maintenance 4 is associated with poor survival and stemness of patients with pancreatic cancer. Co-author DOI 10.1007/s00795-025-00438-y↗
  2. Long-term disease control of GP2-NTRK1 fusion-positive pancreatic adenocarcinoma with liver metastases using sequential tyrosine receptor kinase inhibitors. First author DOI 10.1007/s12328-026-02388-z↗
  3. TMPRSS4 Expression Predicts Survival and Benefit from Neoadjuvant Chemotherapy in Pancreatic Cancer. First author DOI 10.1245/s10434-026-20228-9↗
  4. ASO Visual Abstract: TMPRSS4 Expression Predicts Survival and Benefit From Neoadjuvant Chemotherapy in Pancreatic Cancer. First author DOI 10.1245/s10434-026-20329-5↗
  5. Adjuvant S-1 Plus Metformin after Pancreatic Cancer Resection: A Multicenter Randomized Phase II Trial Co-author DOI 10.21203/rs.3.rs-9445035/v1↗
  6. Patients With Pancreatic Cancer With Synchronous Liver Oligometastasis Show a Significant Long-Term Survival Benefit From Resection Under Specific Conditions: … Co-author DOI 10.1002/jhbp.12181↗
  7. Real-world effectiveness of anamorelin in patients with unresectable and relapse pancreatic cancer: a prospective observational study. Co-author DOI 10.21037/jgo-2025-162↗
  8. Long-term outcomes of neoadjuvant gemcitabine, nab-paclitaxel, and S1 (GAS) in borderline resectable pancreatic cancer with arterial contact: Results from a ph… Co-author DOI 10.1002/jhbp.1412↗
  9. Effects of transmembrane serine protease 4 on the survival in patients with pancreatic ductal adenocarcinoma undergoing surgery followed by adjuvant chemothera… First author DOI 10.1007/s00595-024-02824-y↗
  10. IQ Motif Containing GTPase-Activating Protein 3 Is Associated with Cancer Stemness and Survival in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1159/000535542↗
  11. Effect of body fat mass loss on prognosis of radical resection for pancreatic ductal adenocarcinoma based on bioelectrical impedance analysis. First author DOI 10.1186/s12893-024-02315-4↗
  12. Expression of kinesin family member C1 in pancreatic ductal adenocarcinoma affects tumor progression and stemness. Co-author DOI 10.1016/j.prp.2022.154277↗
  13. Clinical features and images of malignant lymphoma localized in the pancreatic head to differentiate from pancreatic ductal adenocarcinoma: a case series study. Co-author DOI 10.1186/s12876-023-02779-3↗
  14. Long-standing diabetes mellitus increases concomitant pancreatic cancer risk in patients with intraductal papillary mucinous neoplasms. Co-author DOI 10.1186/s12876-022-02564-8↗
  15. High Annexin A10 expression is correlated with poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.14670/hh-18-397↗
  16. Effectiveness of Abdominal Ultrasonography for Improving the Prognosis of Pancreatic Cancer during Medical Checkup: A Single Center Retrospective Analysis. Co-author DOI 10.3390/diagnostics12122913↗
  17. A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial… Co-author DOI 10.1016/j.ejca.2021.10.012↗
  18. Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (… Last author DOI 10.1016/j.ejca.2018.01.081↗
  19. [A Resectable Case of TS-1 Therapy Useful in Distinguishing Primary Lung Cancer from Lung Metastases of Pancreatic Cancer]. Co-author PMID 29362317↗
  20. A phase 1 study of gemcitabine/nab-paclitaxel/S-1 (GAS) combination neoadjuvant chemotherapy for patients with locally advanced pancreatic adenocarcinoma. Co-author DOI 10.1007/s00280-017-3274-0↗
  21. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Co-author DOI 10.1016/s0140-6736(16)30583-9↗
  22. Prognostic impact of dihydropyrimidine dehydrogenase expression on pancreatic adenocarcinoma patients treated with S-1-based adjuvant chemotherapy after surgic… Co-author DOI 10.1002/jso.21955↗
  23. [Adjuvant gemcitabine plus S-1 chemotherapy for pancreatic cancer after surgical resection - outcomes and future perspectives]. Last author PMID 21971141↗

Closest collaborators

The 25 strongest of 77 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sho Tazuma · 8 shared papers, 2023–2026 · strength 1.67
  2. Hirotaka Tashiro · 7 shared papers, 2018–2026 · strength 1.40
  3. Kenta Baba · 4 shared papers, 2024–2026 · strength 1.00
  4. Akira Ishikawa · 5 shared papers, 2022–2026 · strength 0.99
  5. Kenichiro Uemura · 7 shared papers, 2011–2026 · strength 0.98
  6. Atsushi Yamaguchi · 5 shared papers, 2022–2024 · strength 0.83
  7. Shin’ya Takahashi · 5 shared papers, 2017–2024 · strength 0.81
  8. Yosuke Shimizu · 3 shared papers, 2026 · strength 0.79
  9. Shinya Takahashi · 3 shared papers, 2026 · strength 0.79
  10. Tatsuaki Sumiyoshi · 3 shared papers, 2021–2026 · strength 0.63
  11. Yoshiyuki Shibata · 3 shared papers, 2024–2025 · strength 0.60
  12. Naohiro Kato · 3 shared papers, 2022–2025 · strength 0.48
  13. Yoshiaki Murakami · 5 shared papers, 2011–2024 · strength 0.48
  14. Wataru Yasui · 2 shared papers, 2024–2026 · strength 0.47
  15. Shiro Oka · 2 shared papers, 2023–2026 · strength 0.44
  16. Hiroshi Kohno · 3 shared papers, 2022–2023 · strength 0.43
  17. Naru Kondo · 4 shared papers, 2011–2024 · strength 0.43
  18. Aya Kido · 2 shared papers, 2023–2024 · strength 0.36
  19. Naohide Oue · 2 shared papers, 2023–2024 · strength 0.36
  20. Atsushi Yamaguchi · 2 shared papers, 2022–2025 · strength 0.35
  21. Kenjiro Okada · 2 shared papers, 2021–2024 · strength 0.34
  22. Shinji Mii · 1 shared paper, 2026 · strength 0.27
  23. Yasutaka Ishii · 1 shared paper, 2026 · strength 0.27
  24. Yuto Fujiki · 1 shared paper, 2026 · strength 0.27
  25. Satoshi Hirano · 3 shared papers, 2016–2025 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.